

Glaucoma 360 Fosters Collaboration With Industry


The meeting brings together clinicians, key leaders, and the FDA to improve the lives of glaucoma patients.

Glaucoma Research Foundation will host the 6th Annual Glaucoma 360 New Horizons Forum in San Francisco on Feb. 3, 2017. This unique meeting brings together clinicians with key leaders in industry, business, finance, and the FDA to highlight promising advances in glaucoma treatment and diagnostics.

Since the meeting's inception in 2012, 55 early-stage companies have presented their new technologies and developments in glaucoma devices, drug delivery, pharmaceuticals, and disease management. During this time there have been a number of important acquisitions in glaucoma, including AqueSys' acquisition (XEN Gel Stent) by Allergan, InnFocus (MicroShunt) by Santen, and Transcend Medical (CyPass Micro-Stent) by Alcon. These major developments emphasize the rapidly growing importance of the glaucoma market and the increasing prominence and opportunity within microinvasive glaucoma surgery (MIGS).

In addition to highlighting innovative start-up companies, the New Horizons Forum connects entrepreneurs with major industry players to encourage collaboration and nurture future partnerships.

Cynthia Mattox, MD, FACS, a Glaucoma 360 Advisory Board member, said that "industry is eager to find and advance new ideas. They welcome the interaction at Glaucoma 360 with physicians and other entrepreneurs who have novel approaches." Glaucoma 360 offers an exclusive opportunity for this type of interaction between physicians, industry, and early-stage companies that can advance glaucoma treatment and diagnostics and bring them into practice quickly.



At the upcoming 2017 Glaucoma 360 New Horizons Forum, Joel S. Schuman, MD, FACS, will deliver the *Drs. Henry and Frederick Sutro Memorial Lecture* to begin a full day of presentations and panel discussions featuring innovations in glaucoma drug delivery, pharmaceuticals, and devices. There will also be sessions focusing on working with the FDA and securing venture capital funding. New elements for the 2017 program include a segment on telemedicine moderated by Lama Al-Aswad, MD, and Louis R. Pasquale, MD.

The New Horizons Forum is the centerpiece of Glaucoma 360, which includes the Annual Gala on Feb. 2 to benefit Glaucoma Research Foundation's research and patient education programs. Glaucoma 360 closes on Feb. 4 with the 21st Annual Glaucoma Symposium CME and 2nd Annual Glaucoma Symposium CE, which highlight the latest advancements in glaucoma for practicing ophthalmologists and optometrists. ■

To learn more and register, visit www.glaucoma360.org.